LY3009120,1454682-72-4

MCE 的所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务。

LY3009120

CAS No. : 1454682-72-4

MCE 国际站：LY3009120

产品活性：LY3009120 (DP-4978) 是泛 RAF 抑制剂，其抑制BRAF^V600E，BRAF^WT 和CRAF^WT 的 IC₅₀ 分别为 5.8，9.1和15 nM。

研究领域：MAPK/ERK Pathway  |  Autophagy

作用靶点：Raf  |  Autophagy

In Vitro: In the whole-cell based KiNativ assay, LY3009120 shows affinity to each RAF isoform with the IC₅₀ of 44, 31-47 and 42 nM for ARAF, BRAF and CRAF respectively. LY3009120 exhibits anti-proliferative effects on cell lines harboring BRAF^V600E, KRAS^G13 and KRAS^G12 mutations. LY3009120 (1 μM) inhibits the phosphorylation of both MEK1/2 and ERK1/2 in cell lines with high basal levels of pMEK1/2 and pERK1/2 (RKO and HCT 116). LY3009120 shows inhibitory effect on tumor cells such as BxPC-3, NCI-H2405 and OV-90 cell lines. LY3009120 (0.01 μM) demonstrates potent and dose-dependent inhibition of phospho-MEK and ERK in all three cell lines. LY3009120 demonstrates a concentration-dependent cell growth inhibition with IC₅₀ values of 0.04, 0.087, and 0.007 μM against H2405, BxPC-3, and OV-90 cells, respectively. LY3009120 inhibits BRAF^WT, CRAF^WT, BRAF^V600E, and BRAF^V600E+G468A with the IC₅₀ values of 9.1, 15, 5.8, and 17 nM, respectively. LY3009120 induces BRAF-CRAF dimerization but inhibits the phosphorylation of downstream MEK and ERK. LY3009120 also inhibits various forms of RAF dimers including BRAF or CRAF homodimers. LY3009120 gives only very minor activation at very low doses, with near complete inhibition of phospho-ERK at concentrations above 100 nM.

In Vivo: LY3009120 (20 mg/kg bid) displays significant activity in in vivo BRAF^mut and KRAS^mut CRC xenograft models. In Colo 205 xenografts (BRAF^mut), LY3009120 results in statistically significant tumor regression, while treatment of HCT 116 xenografts (KRAS^mut) results in statistically significant inhibition of tumor growth. LY3009120 treatment reduces pMEK1/2 in all HT-29 xenografts and reduces pERK1/2 in the majority of HT-29 xenografts. LY3009120 (15 or 30 mg/kg) achieves almost complete tumor growth regression, and inhibits downstream phospho-MEK and ERK by approximately 70% and 60%, respectively, in the H2405 model.

相关产品：Covalent Screening Library Plus  |  Clinical Compound Library Plus  |  Bioactive Compound Library Plus  |  Immunology/Inflammation Compound Library  |  Kinase Inhibitor Library  |  MAPK Compound Library  |  Anti-Cancer Compound Library  |  Clinical Compound Library  |  Autophagy Compound Library  |  Covalent Screening Library  |  Oxygen Sensing Compound Library  |  Ferroptosis Compound Library  |  Glutamine Metabolism Compound Library  |  Anti-Lung Cancer Compound Library  |  Anti-Pancreatic Cancer Compound Library  |  Anti-Obesity Compound Library  |  Anti-Liver Cancer Compound Library   |  Anti-Colorectal Cancer Compound Library   |  Heterocyclic Compound Library  |  Membrane Protein-targeted Compound Library  |  Membrane Receptor-targeted Compound Library  |  Cell Death Library  |  Serine/Threonine Kinase Inhibitor Library  |  Sorafenib  |  Dabrafenib  |  Vemurafenib  |  Regorafenib  |  Doramapimod  |  Encorafenib  |  SB-590885  |  PLX-4720  |  Belvarafenib  |  GDC-0879  |  AZ 628  |  Avutometinib  |  GW 5074  |  LXH254  |  Tovorafenib  |  Exarafenib  |  TAK-632  |  Lifirafenib  |  Agerafenib  |  RAF265  |  CCT196969  |  Rineterkib  |  ZM 336372  |  BI-882370  |  R18 TFA

热门产品线：重组蛋白  |  化合物库  |  天然产物  |  荧光染料  |  PROTAC  |  同位素标记物

Trending products：Recombinant Proteins  |  Bioactive Screening Libraries  |  Natural Products  |  Dye Reagents  |  PROTAC  |  Isotope-Labeled Compounds